Cardiff Oncology (CRDF) AI Stock Analysis

• Market Cap: $106.43M
• Dividend Yield: N/A
• Average Volume (3M): 1.46M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.29
• Revenue Growth: -27.29%
• EPS Growth: 16.40%
• Country: US
• Employees: 32
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.17
• Shares Outstanding: 67,360,565
• 10 Day Avg. Volume: 2,841,713
• 30 Day Avg. Volume: 1,462,701
• PEG Ratio: -2.12
• Price to Book (P/B): 2.49
• Price to Sales (P/S): 302.78
• P/FCF Ratio: -5.47
• Enterprise Value/Market Cap: 0.85
• Enterprise Value/Revenue: 180.78
• Enterprise Value/Gross Profit: -8.17
• Enterprise Value/Ebitda: -1.74
• 1Y Price Target: $13.67
• Price Target Upside: 765.19% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: $1.50 ▼(-5.06% Downside)

CRDF scores low primarily due to weak financial performance (minimal revenue, heavy losses, and substantial ongoing cash burn), reinforced by bearish technicals with the stock trading far below major moving averages. Corporate events provide a modest positive catalyst via leadership changes aimed at advancing the lead program, but valuation is difficult to support with negative earnings and no dividend.

Positive Factors

Progress toward registrational trial

Advancing a clearly defined registrational plan is a durable positive: it signals the program has shown sufficient Phase 2 activity to justify pivotal testing, creates a pathway to regulatory approval in 1L RAS‑mutated mCRC, and enables longer‑term commercial and partnership planning if confirmatory results hold.

Clinical differentiation in Phase 2

Dose-dependent efficacy signals relative to standard of care are a structural strength: durable clinical differentiation can support regulatory labeling, physician adoption, and pricing power. If replicated in registrational trials, this underpins a sustainable commercial proposition and partnering leverage.

Low financial leverage

Very low debt is a lasting balance-sheet advantage for a cash‑burning biotech: it reduces near‑term default risk, preserves flexibility to structure financings or collaborations, and avoids interest burdens that could constrain funding for costly late‑stage trials over the coming 2–6 months.

Negative Factors

High cash burn and negative operating cash flow

Sustained negative operating and free cash flow at material levels creates a structural funding requirement: the company will likely need external capital or partnerships to complete registrational studies, increasing dilution or deal-dependency and constraining strategic optionality over the medium term.

Erosion of equity and asset base

Material declines in equity and total assets reflect cumulative losses and cash burn, weakening the company's internal financing capacity. This structural erosion reduces resilience to adverse trial outcomes and increases reliance on external, potentially dilutive capital at a pivotal development stage.

Minimal revenue and deep operating losses

Very low recurring revenue and large net losses are enduring fundamentals for a clinical‑stage biotech: absence of commercial cashflow means the company must rely on financing or partnerships to sustain development, increasing execution risk and potential dilution during the next phases of clinical advancement.

Cardiff Oncology Business Overview & Revenue Model

Company Description

Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

How the Company Makes Money

Cardiff Oncology makes money through a combination of funding sources typical of clinical-stage biotech companies, such as equity financing, grants, and strategic partnerships. As a company focused on drug development, Cardiff Oncology does not yet generate revenue from product sales. Instead, it relies on raising capital through public and private offerings of its stock to fund its research and development activities. Additionally, the company may receive milestone payments or licensing fees from collaborations with larger pharmaceutical companies interested in its drug candidates. These partnerships can provide crucial financial support and resources needed to advance their clinical trials and bring their products closer to commercialization.

Cardiff Oncology Financial Statement Overview

Summary

Overall fundamentals are weak: very small TTM revenue ($0.5M) with a decline, and deep losses (TTM net income -$50.4M) alongside very negative operating/net margins. Cash flow is a key risk with large ongoing cash burn (TTM operating cash flow -$42.2M; free cash flow -$42.3M), implying continued financing needs. The main offset is low leverage (debt-to-equity ~0.02), but shrinking equity/assets and sharply negative ROE (~-77%) highlight value erosion.

Income Statement

TTM (Trailing-Twelve-Months) revenue remains very small ($0.5M) and declined (-8.2%), highlighting limited scale. Profitability is weak: the company is deeply loss-making (TTM net income -$50.4M) with extremely negative net and operating margins, which worsened versus annual 2024 as losses outpaced revenue. A positive is that revenue has shown growth in several prior years (2022–2024), but the overall earnings profile is still dominated by heavy operating losses.

Balance Sheet

The balance sheet shows low leverage, with debt modest relative to equity (TTM debt-to-equity ~0.02), which reduces financial risk. However, equity and total assets have contracted materially over time (equity down from ~$140.4M in 2021 to ~$48.8M TTM; assets down from ~$149.5M to ~$63.8M), reflecting sustained losses and cash burn. Returns on equity are sharply negative (TTM ROE about -77%), indicating significant value erosion despite low debt.

Cash Flow

Cash generation is weak, with consistently negative operating cash flow and free cash flow (TTM operating cash flow -$42.2M; TTM free cash flow -$42.3M), implying ongoing funding needs. A modest positive is that free cash flow deterioration appears to be stabilizing on a growth basis in TTM, but the absolute level of cash burn remains high. Free cash flow is roughly in line with net loss (TTM free cash flow to net income ~1.0), suggesting losses are translating into real cash outflows rather than being largely non-cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	501.00K	683.00K	488.00K	386.00K	359.00K	366.00K
Gross Profit	-11.08M	683.00K	488.00K	386.00K	359.00K	366.00K
EBITDA	-52.08M	-48.25M	-45.01M	-39.67M	-28.40M	-18.84M
Net Income	-50.42M	-45.43M	-41.44M	-38.70M	-28.29M	-19.31M
Balance Sheet
Total Assets	63.78M	97.19M	81.64M	116.19M	149.54M	134.73M
Cash, Cash Equivalents and Short-Term Investments	60.59M	91.75M	74.82M	105.27M	140.82M	130.98M
Total Debt	1.01M	1.52M	2.15M	2.71M	3.12M	869.00K
Total Liabilities	14.99M	14.24M	11.90M	9.85M	9.13M	6.57M
Stockholders Equity	48.79M	82.95M	69.74M	106.34M	140.42M	128.16M
Cash Flow
Free Cash Flow	-42.27M	-37.77M	-31.47M	-34.71M	-23.25M	-16.53M
Operating Cash Flow	-42.22M	-37.69M	-30.89M	-33.82M	-23.04M	-16.32M
Investing Cash Flow	-4.90M	13.73M	36.20M	38.15M	-131.45M	-211.00K
Financing Cash Flow	44.22M	53.78M	0.00	75.00K	35.45M	137.31M

Cardiff Oncology Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.58
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRDF, the sentiment is Negative. The current price of 1.58 is below the 20-day moving average (MA) of 2.51, below the 50-day MA of 2.50, and below the 200-day MA of 2.69, indicating a bearish trend. The MACD of -0.29 indicates Positive momentum. The RSI at 27.47 is Positive, neither overbought nor oversold. The STOCH value of 5.88 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CRDF.

Cardiff Oncology Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ONCY	52 Neutral	$96.85M	―	-745.66%	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AVTX	47 Neutral	$266.03M	-1.65	-174.79%	―	-76.59%	94.03%
PYXS	45 Neutral	$94.02M	-0.95	-87.28%	―	-82.53%	-52.00%
CRDF	44 Neutral	$106.43M	-1.99	-102.71%	―	-27.29%	16.40%
MOLN	42 Neutral	$182.63M	-2.30	-49.86%	―	-100.00%	11.02%

Cardiff Oncology Corporate Events

Cardiff Oncology Overhauls Leadership to Advance Onvansertib

On January 27, 2026, Cardiff Oncology announced a major executive leadership transition as it prepares to move its lead cancer therapy, onvansertib, toward late-stage clinical development. Board member and experienced biotech executive Mani Mohindru, PhD, was appointed interim Chief Executive Officer, while CEO Mark Erlander, PhD, and CFO James Levine stepped down from their roles; the company also promoted long-time finance executive Brigitte Lindsay to Chief Accounting Officer and launched a search for permanent CEO and CFO successors. Management and board statements framed these changes as aligning Cardiff’s executive and financial leadership with the demands of advancing onvansertib in first-line RAS‑mutated metastatic colorectal cancer and broadening its potential across other difficult‑to‑treat cancers, signaling an intensified focus on execution, clinical progress and strategic positioning at a pivotal stage in the company’s development.

The most recent analyst rating on (CRDF) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Cardiff Oncology stock, see the CRDF Stock Forecast page.